BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer

被引:24
|
作者
Li, Da [1 ]
Chen, Na-Na [2 ]
Cao, Ji-Min [3 ]
Sun, Wu-Ping [4 ]
Zhou, Yi-Ming [4 ]
Li, Chun-Yan [5 ]
Wang, Xiu-Xia [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China
[2] Nagoya Univ, Grad Sch Med, Dept Mol Immunol, Nagoya, Aichi 4648601, Japan
[3] Chinese Acad Med Sci, Dept Physiol & Pathophysiol, Inst Basic Med Sci, Peking Union Med Coll,Sch Basic Med, Beijing 100730, Peoples R China
[4] Natl Inst Physiol Sci, Div Cell Signaling, Okazaki, Aichi 444, Japan
[5] Chinese Acad Med Sci, Peking Union Med Coll, Sch Basic Med, Dept Histol & Embryol,Inst Basic Med, Beijing 100730, Peoples R China
关键词
BRCA1; NAD; NADH; Nampt; ovarian cancer; breast cancer type 1 susceptibility protein; CtBP; C-terminal binding proteins; nicotinamide adenine dinucleotide; nicotinamide phosphoribosyltransferase; PCR; polymerase chain reaction; shRNAs; short hairpin ribonucleic acids; TRANSCRIPTIONAL REGULATION; BREAST-CANCER; RECEPTOR; EXPRESSION; IDENTIFICATION; CROSSTALK; CELLS;
D O I
10.4161/15384101.2015.942208
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Both hereditary factors (e.g., BRCA1) and nicotinamide adenine dinucleotide (NAD)-dependent metabolic pathways are implicated in the initiation and progression of ovarian cancer. However, whether crosstalk exists between BRCA1 and NAD metabolism remains largely unknown. Here, we showed that: (i) BRCA1 inactivation events (mutation and promoter methylation) were accompanied by elevated levels of NAD; (ii) the knockdown or overexpression of BRCA1 was an effective way to induce an increase or decrease of nicotinamide phosphoribosyltransferase (Nampt)-related NAD synthesis, respectively; and (iii) BRCA1 expression patterns were inversely correlated with NAD levels in human ovarian cancer specimens. In addition, it is worth noting that: (i) NAD incubation induced increased levels of BRCA1 in a concentration-dependent manner; (ii) Nampt knockdown-mediated reduction in NAD levels was effective at inhibiting BRCA1 expression; and (iii) the overexpression of Nampt led to higher NAD levels and a subsequent increase in BRCA1 levels in primary ovarian cancer cells and A2780, HO-8910 and ES2 ovarian cancer cell lines. These results highlight a novel link between BRCA1 and NAD. Our findings imply that genetic (e.g., BRCA1 inactivation) and NAD-dependent metabolic pathways are jointly involved in the malignant progression of ovarian cancer.
引用
收藏
页码:2564 / 2571
页数:8
相关论文
共 50 条
  • [31] Prediction of BRCA1 Germline Mutation Status in Women With Ovarian Cancer Using Morphology-based Criteria Identification of a BRCA1 Ovarian Cancer Phenotype
    Fujiwara, Mika
    McGuire, Valerie A.
    Felberg, Anna
    Sieh, Weiva
    Whittemore, Alice S.
    Longacre, Teri A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (08) : 1170 - 1177
  • [32] BRCA1 founder mutations compared to ovarian cancer in Belarus
    Savanevich, Alena
    Oszurek, Oleg
    Lubinski, Jan
    Cybulski, Cezary
    Debniak, Tadeusz
    Narod, Steven A.
    Gronwald, Jacek
    FAMILIAL CANCER, 2014, 13 (03) : 445 - 447
  • [33] Nicotinamide Adenine Dinucleotide (NAD+) Repletion Attenuates Bupivacaine-Induced Neurotoxicity
    Ting Zheng
    Shi Yuan Xu
    Shu Qin Zhou
    Lu Ying Lai
    Le Li
    Neurochemical Research, 2013, 38 : 1880 - 1894
  • [34] Can Nicotinamide Adenine Dinucleotide (NAD+) and Sirtuins Be Harnessed to Improve Mare Fertility?
    Pollard, Charley-Lea
    ANIMALS, 2024, 14 (02):
  • [35] Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer
    Choi, Min Chul
    Jang, Ja-Hyun
    Jung, Sang Geun
    Park, Hyun
    Joo, Won Duk
    Song, Seung Hun
    Lee, Chan
    Lee, Je Ho
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (02) : 308 - 315
  • [36] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Zaaijer, Leendert H.
    van Doorn, Helena C.
    Mourits, Marian J. E.
    van Beurden, Marc
    de Hullu, Joanne A.
    Adank, Muriel A.
    van Lonkhuijzen, Luc R. C. W.
    Vasen, Hans F. A.
    Slangen, Brigitte F. M.
    Gaarenstroom, Katja N.
    Zweemer, Ronald P.
    Vencken, Peggy M. L. H.
    Seynaeve, Caroline
    Kriege, Mieke
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1174 - 1178
  • [37] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Leendert H Zaaijer
    Helena C van Doorn
    Marian J E Mourits
    Marc van Beurden
    Joanne A de Hullu
    Muriel A Adank
    Luc R C W van Lonkhuijzen
    Hans F A Vasen
    Brigitte F M Slangen
    Katja N Gaarenstroom
    Ronald P Zweemer
    Peggy M L H Vencken
    Caroline Seynaeve
    Mieke Kriege
    British Journal of Cancer, 2016, 115 : 1174 - 1178
  • [38] BRCA1: An Endocrine and Metabolic Regulator
    Werner, Haim
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [39] The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania
    Elsakov, P.
    Kurtinaitis, J.
    Petraitis, S.
    Ostapenko, V.
    Razumas, M.
    Razumas, T.
    Meskauskas, R.
    Petrulis, K.
    Luksite, A.
    Lubinski, J.
    Gorski, B.
    Narod, S. A.
    Gronwald, J.
    CLINICAL GENETICS, 2010, 78 (04) : 373 - 376
  • [40] Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation
    Stewart, James
    George, Angela
    Banerjee, Susana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 947 - 958